Weijun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Weijun Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Jinjin Liu
Tianjin NanKai Hospital, Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Institute of Integrative Medicine for Acute Abdominal Diseases, No. 6 Changjiang Road, Nankai District, Tianjin 300100, China
3 shared publicationsTeng Wu
Tianjin NanKai Hospital, Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Institute of Integrative Medicine for Acute Abdominal Diseases, No. 6 Changjiang Road, Nankai District, Tianjin 300100, China
3 shared publicationsDonghua Li
Tianjin NanKai Hospital, Tianjin Key Laboratory of Acute Abdomen Disease Associated Organ Injury and ITCWM Repair, Institute of Integrative Medicine for Acute Abdominal Diseases, No. 6 Changjiang Road, Nankai District, Tianjin 300100, China
2 shared publicationsHugh Smyth
2 shared publicationsYunfeng Cui
2 shared publications- Ling Wei
School of Chinese Materia Medica, Guangdong Pharmaceutical University, Guangzhou 510006, China
1 shared publication
Latest Publications
- 13 November 2023
- Published by Elsevier in Fitoterapia
- Vol. 172, 105746
Therapeutic effect of yinchenhao decoction on cholelithiasis via mucin in the gallbladder and intestine
- 13 November 2023
- Published by Elsevier in Fitoterapia
- Vol. 172, 105746
Therapeutic effect of yinchenhao decoction on cholelithiasis via mucin in the gallbladder and intestine
- Open Access
- 10 November 2022
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 78
The effect of mucin on supersaturation of poorly water-soluble drugs with different crystallization behavior and in vitro-in vivo correlation
- 10 November 2022
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 78
Open AccessThe effect of mucin on supersaturation of poorly water-soluble drugs with different crystallization behavior and in vitro-in vivo correlation
- Open Access
- 5 October 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-11
Studies on the Incompatibility between Bulbus fritillariae and Radix aconiti praeparata Based on the P-gp
Bulbus fritillariae and Radix aconiti praeparata are an incompatible herbal pair in the traditional Chinese medicine theory eighteen incompatible medicaments, and they should not be used simultaneously in clinical treatment for safety. This study aimed to investigate the incompatibility mechanism between Bulbus fritillariae and Radix aconiti praeparata based on their interaction with P-glycoprotein (P-gp). The interaction between Bulbus fritillariae and Radix aconiti praeparata during in vitro decocting as well as in vivo absorption was investigated by determining the dry extract yield and by rat single-pass intestinal perfusion (SPIP) model. Inhibition of different species of Bulbus fritillariae on P-gp function was examined using the SPIP model. The mRNA and protein expression of P-gp was determined by PCR and western blotting. The active ingredients of Bulbus fritillariae were predicted and screened for inhibiting P-gp activity by Schrodingers molecular docking and MDR1-MDCK cell transport study, respectively. Mediation of monoester alkaloids in Radix aconiti praeparata by P-gp was predicted and examined using Schrodingers molecular docking and SPIP experiment, respectively. In the results, when Radix aconiti praeparata was combined with Bulbus fritillariae, the toxic ingredient benzoylmesaconine in Radix aconiti praeparata displayed higher intestinal permeability, whereas the toxic ingredients showed no significant difference during the in vitro decoction process. Bulbus fritillariae thunbergii inhibited both the P-gp function and expression; in contrast, Bulbus fritillariae cirrhosae inhibited the function only. Alkaloids including peimine, peimisine, and imperialine were the active ingredients for inhibiting P-gp activity. Benzoylmesaconine in Radix aconiti praeparata was the substrate of P-gp.
- 5 October 2021
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2021, 1-11
Open AccessStudies on the Incompatibility between Bulbus fritillariae and Radix aconiti praeparata Based on the P-gp
Bulbus fritillariae and Radix aconiti praeparata are an incompatible herbal pair in the traditional Chinese medicine theory eighteen incompatible medicaments, and they should not be used simultaneously in clinical treatment for safety. This study aimed to investigate the incompatibility mechanism between Bulbus fritillariae and Radix aconiti praeparata based on their interaction with P-glycoprotein (P-gp). The interaction between Bulbus fritillariae and Radix aconiti praeparata during in vitro decocting as well as in vivo absorption was investigated by determining the dry extract yield and by rat single-pass intestinal perfusion (SPIP) model. Inhibition of different species of Bulbus fritillariae on P-gp function was examined using the SPIP model. The mRNA and protein expression of P-gp was determined by PCR and western blotting. The active ingredients of Bulbus fritillariae were predicted and screened for inhibiting P-gp activity by Schrodingers molecular docking and MDR1-MDCK cell transport study, respectively. Mediation of monoester alkaloids in Radix aconiti praeparata by P-gp was predicted and examined using Schrodingers molecular docking and SPIP experiment, respectively. In the results, when Radix aconiti praeparata was combined with Bulbus fritillariae, the toxic ingredient benzoylmesaconine in Radix aconiti praeparata displayed higher intestinal permeability, whereas the toxic ingredients showed no significant difference during the in vitro decoction process. Bulbus fritillariae thunbergii inhibited both the P-gp function and expression; in contrast, Bulbus fritillariae cirrhosae inhibited the function only. Alkaloids including peimine, peimisine, and imperialine were the active ingredients for inhibiting P-gp activity. Benzoylmesaconine in Radix aconiti praeparata was the substrate of P-gp.
- Open Access
- 8 April 2021
- Published by Springer Nature in Research Square
Therapeutic effect of yinchenhao decoction on cholelithiasis via mucin from gallbladder-intestine
Background: Cholelithiasis, known as gallstone, was a common and frequently occurring disease worldwide. Mucus was a viscoelastic protective layer lining the surface of mucosa and synthesized by specialized epithelial cells. Yinchenhao decoction was a classic prescription, first documented in Treatise on Febrile Disease. It had a definite and significant therapeutic effect on cholelithiasis, used as a complement to surgery. Our study aimed to investigate the pathological mechanism of cholelithiasis and the therapeutic mechanism of yinchenhao decoction via mucin from gallbladder-intestine.Methods: The solubility of cholesterol in fasted state simulated intestinal fluid (FaSSIF) without and with mucin was tested. The experiment of supersaturation stability was designed by solvent-shift method. The animal experiment was performed by cholelithiasis model of high cholesterol diet. The stones were observed and the related lipid was tested by automatic biochemical analyzer. The mucin was detected by PCR and western blot. Statistics was analyzed using χ2-tests and t-tests.Results: There was no significant difference in the solubility of cholesterol between FaSSIF without and with mucin. Tss or AUC significantly increased with addition of mucin to FaSSIF (pConclusions: In cholelithiasis, the mucin in gallbladder (MUC5AC) highly expressed, shortened cholesterol supersaturation, and promoted cholesterol crystallization; the mucin in small intestine (MUC2) highly expressed, prolonged cholesterol supersaturation, and promoted cholesterol absorption. The yinchenhao decoction inhibited the expression of mucin from gallbladder-intestine for the treatment of cholelithiasis.
- 8 April 2021
- Published by Springer Nature in Research Square
Open AccessTherapeutic effect of yinchenhao decoction on cholelithiasis via mucin from gallbladder-intestine
Background: Cholelithiasis, known as gallstone, was a common and frequently occurring disease worldwide. Mucus was a viscoelastic protective layer lining the surface of mucosa and synthesized by specialized epithelial cells. Yinchenhao decoction was a classic prescription, first documented in Treatise on Febrile Disease. It had a definite and significant therapeutic effect on cholelithiasis, used as a complement to surgery. Our study aimed to investigate the pathological mechanism of cholelithiasis and the therapeutic mechanism of yinchenhao decoction via mucin from gallbladder-intestine.Methods: The solubility of cholesterol in fasted state simulated intestinal fluid (FaSSIF) without and with mucin was tested. The experiment of supersaturation stability was designed by solvent-shift method. The animal experiment was performed by cholelithiasis model of high cholesterol diet. The stones were observed and the related lipid was tested by automatic biochemical analyzer. The mucin was detected by PCR and western blot. Statistics was analyzed using χ2-tests and t-tests.Results: There was no significant difference in the solubility of cholesterol between FaSSIF without and with mucin. Tss or AUC significantly increased with addition of mucin to FaSSIF (pConclusions: In cholelithiasis, the mucin in gallbladder (MUC5AC) highly expressed, shortened cholesterol supersaturation, and promoted cholesterol crystallization; the mucin in small intestine (MUC2) highly expressed, prolonged cholesterol supersaturation, and promoted cholesterol absorption. The yinchenhao decoction inhibited the expression of mucin from gallbladder-intestine for the treatment of cholelithiasis.